(ORGO) Organogenesis Holdings - Ratings and Ratios
Wound Grafts, Skin Substitutes, Nerve Wrap
ORGO EPS (Earnings per Share)
ORGO Revenue
Description: ORGO Organogenesis Holdings
Organogenesis Holdings Inc. is a regenerative medicine company specializing in advanced wound care and surgical medicine markets. The companys product portfolio includes bioengineered skin substitutes like Apligraf and Dermagraft, as well as placental allografts such as Affinity and Novachor, which serve as protective barriers and extracellular matrix scaffolds for wound care.
Key Performance Indicators (KPIs) to monitor Organogenesis Holdings Inc.s performance include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. Given the companys focus on regenerative medicine, tracking the adoption rates of its flagship products, such as Apligraf and PuraPly, is crucial. Additionally, monitoring the progress of its pipeline products, like ReNu, which is in Phase 3 trials for knee osteoarthritis, is essential to understanding the companys future growth prospects.
The companys sales strategy, which involves direct sales representatives and independent agencies, targets hospitals, wound care centers, and physician offices. To gauge the effectiveness of this strategy, metrics such as sales force effectiveness, customer acquisition costs, and customer retention rates should be closely monitored. Furthermore, tracking the competitive landscape, including market share and competitor product offerings, will provide valuable insights into Organogenesis Holdings Inc.s market position.
From a financial perspective, Organogenesis Holdings Inc.s market capitalization and forward price-to-earnings ratio suggest that investors are expecting growth in the companys earnings. To justify this expectation, the company must demonstrate continued revenue growth, expansion of its product portfolio, and successful commercialization of its pipeline products. As such, investors should closely monitor the companys quarterly earnings reports and guidance, as well as updates on its R&D pipeline.
ORGO Stock Overview
| Market Cap in USD | 629m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-01-05 |
ORGO Stock Ratings
| Growth Rating | 35.0% |
| Fundamental | 29.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 43.1% |
| Analyst Rating | 4.50 of 5 |
ORGO Dividends
Currently no dividends paidORGO Growth Ratios
| Growth Correlation 3m | 81.2% |
| Growth Correlation 12m | 57.5% |
| Growth Correlation 5y | -56.9% |
| CAGR 5y | 14.26% |
| CAGR/Max DD 3y | 0.25 |
| CAGR/Mean DD 3y | 0.49 |
| Sharpe Ratio 12m | 0.54 |
| Alpha | 0.08 |
| Beta | 0.475 |
| Volatility | 76.12% |
| Current Volume | 477.6k |
| Average Volume 20d | 535.2k |
| Stop Loss | 4.5 (-7.4%) |
| Signal | -0.69 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-11.0m TTM) > 0 and > 6% of Revenue (6% = 25.8m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -1.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 45.25% (prev 33.11%; Δ 12.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -33.2m <= Net Income -11.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (126.9m) change vs 12m ago -4.31% (target <= -2.0% for YES) |
| Gross Margin 73.03% (prev 74.23%; Δ -1.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.00% (prev 101.2%; Δ -6.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.73 (EBITDA TTM -1.41m / Interest Expense TTM 2.16m) >= 6 (WARN >= 3) |
Altman Z'' 1.35
| (A) 0.42 = (Total Current Assets 260.2m - Total Current Liabilities 65.8m) / Total Assets 461.1m |
| (B) -0.15 = Retained Earnings (Balance) -68.3m / Total Assets 461.1m |
| (C) -0.03 = EBIT TTM -14.5m / Avg Total Assets 452.1m |
| (D) -0.68 = Book Value of Equity -68.3m / Total Liabilities 99.9m |
| Total Rating: 1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.70
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield 0.70% = 0.35 |
| 3. FCF Margin 0.97% = 0.24 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda -31.16 = -2.50 |
| 6. ROIC - WACC (= -12.72)% = -12.50 |
| 7. RoE -3.15% = -0.53 |
| 8. Rev. Trend -28.43% = -2.13 |
| 9. EPS Trend -44.47% = -2.22 |
What is the price of ORGO shares?
Over the past week, the price has changed by -0.61%, over one month by +6.11%, over three months by +50.00% and over the past year by +69.93%.
Is Organogenesis Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ORGO is around 5.10 USD . This means that ORGO is currently overvalued and has a potential downside of 4.94%.
Is ORGO a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ORGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 64.6% |
| Analysts Target Price | 8 | 64.6% |
| ValueRay Target Price | 5.6 | 15.6% |
Last update: 2025-09-05 04:54
ORGO Fundamental Data Overview
CCE Cash And Equivalents = 73.1m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 12.3153
P/S = 1.4649
P/B = 2.6977
Beta = 1.77
Revenue TTM = 429.5m USD
EBIT TTM = -14.5m USD
EBITDA TTM = -1.41m USD
Long Term Debt = 34.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 9.77m USD (from shortTermDebt, last quarter)
Debt = 43.8m USD (Calculated: Short Term 9.77m + Long Term 34.1m)
Net Debt = -32.3m USD (from netDebt column, last quarter)
Enterprise Value = 600.0m USD (629.2m + Debt 43.8m - CCE 73.1m)
Interest Coverage Ratio = -6.73 (Ebit TTM -14.5m / Interest Expense TTM 2.16m)
FCF Yield = 0.70% (FCF TTM 4.18m / Enterprise Value 600.0m)
FCF Margin = 0.97% (FCF TTM 4.18m / Revenue TTM 429.5m)
Net Margin = -2.56% (Net Income TTM -11.0m / Revenue TTM 429.5m)
Gross Margin = 73.03% ((Revenue TTM 429.5m - Cost of Revenue TTM 115.9m) / Revenue TTM)
Tobins Q-Ratio = -8.78 (set to none) (Enterprise Value 600.0m / Book Value Of Equity -68.3m)
Interest Expense / Debt = 1.53% (Interest Expense 669.0k / Debt 43.8m)
Taxrate = 21.0% (US default)
NOPAT = -14.5m (EBIT -14.5m, no tax applied on loss)
Current Ratio = 3.95 (Total Current Assets 260.2m / Total Current Liabilities 65.8m)
Debt / Equity = 0.12 (Debt 43.8m / last Quarter total Stockholder Equity 361.2m)
Debt / EBITDA = -31.16 (Net Debt -32.3m / EBITDA -1.41m)
Debt / FCF = 10.50 (Debt 43.8m / FCF TTM 4.18m)
Total Stockholder Equity = 348.3m (last 4 quarters mean)
RoA = -2.38% (Net Income -11.0m, Total Assets 461.1m )
RoE = -3.15% (Net Income TTM -11.0m / Total Stockholder Equity 348.3m)
RoCE = -3.80% (Ebit -14.5m / (Equity 348.3m + L.T.Debt 34.1m))
RoIC = -5.39% (NOPAT -14.5m / Invested Capital 269.9m)
WACC = 7.33% (E(629.2m)/V(673.1m) * Re(7.76%)) + (D(43.8m)/V(673.1m) * Rd(1.53%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -10.69 | Cagr: -0.38%
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈5.91m ; Y1≈3.88m ; Y5≈1.78m
Fair Price DCF = 0.28 (DCF Value 34.9m / Shares Outstanding 126.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -44.47 | EPS CAGR: -31.67% | SUE: -0.73 | # QB: 0
Revenue Correlation: -28.43 | Revenue CAGR: -5.16% | SUE: N/A | # QB: None
Additional Sources for ORGO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle